tiprankstipranks
Advertisement
Advertisement

AZN Stock Latest News

AstraZeneca’s CHRONICLES COPD Study Completion: What It Means for AZN Investors
Company AnnouncementsAstraZeneca’s CHRONICLES COPD Study Completion: What It Means for AZN Investors
5h ago
AZN
AstraZeneca: SERENA-4 Opportunity Supports Maintained Buy Rating and Unchanged $16,500 Price Target
PremiumRatings
AstraZeneca: SERENA-4 Opportunity Supports Maintained Buy Rating and Unchanged $16,500 Price Target
10h ago
AZN
CMS proposes to lock in lower prices in Medicare drug price negotiation program
PremiumThe Fly
CMS proposes to lock in lower prices in Medicare drug price negotiation program
9d ago
AZN
BMY
AstraZeneca’s sBLA for Ultomiris granted Priority Review by U.S. FDA
PremiumThe Fly
AstraZeneca’s sBLA for Ultomiris granted Priority Review by U.S. FDA
9d ago
AZN
AstraZeneca Wins First Targeted U.S. Approval for PTEN-Deficient Metastatic Prostate Cancer
PremiumCompany Announcements
AstraZeneca Wins First Targeted U.S. Approval for PTEN-Deficient Metastatic Prostate Cancer
10d ago
AZN
Roche reports FDA approval for prostate cancer companion diagnostic
PremiumThe FlyRoche reports FDA approval for prostate cancer companion diagnostic
12d ago
AZN
CHRO
Truqap approved for PTEN-deficient metastatic hormone-sensitive prostate cancer
Premium
The Fly
Truqap approved for PTEN-deficient metastatic hormone-sensitive prostate cancer
12d ago
AZN
AstraZeneca’s GRANITE Study Puts Airsupra’s Real‑World Edge Over Albuterol to the Test
Premium
Company Announcements
AstraZeneca’s GRANITE Study Puts Airsupra’s Real‑World Edge Over Albuterol to the Test
12d ago
AZN
Analyst James Quigley Reiterates Buy on AstraZeneca, Citing Undervalued Pipeline‑Driven Growth Upside
PremiumRatings
Analyst James Quigley Reiterates Buy on AstraZeneca, Citing Undervalued Pipeline‑Driven Growth Upside
15d ago
AZN
AstraZeneca: Breast Cancer Pipeline Strength Supports Buy Rating as Sachin Jain Reiterates Unchanged 16,500 GBp Price Target
PremiumRatings
AstraZeneca: Breast Cancer Pipeline Strength Supports Buy Rating as Sachin Jain Reiterates Unchanged 16,500 GBp Price Target
15d ago
AZN
AstraZeneca advancing elecoglipron into Phase 3 program in obesity, T2D
PremiumThe Fly
AstraZeneca advancing elecoglipron into Phase 3 program in obesity, T2D
16d ago
AZN
Analyst Reaffirms Buy on AstraZeneca, Citing Underappreciated Non‑Oncology Growth and Blockbuster Pipeline Upside
PremiumRatings
Analyst Reaffirms Buy on AstraZeneca, Citing Underappreciated Non‑Oncology Growth and Blockbuster Pipeline Upside
19d ago
AZN
Acting FDA head vows to block political interference, Endpoint News says
PremiumThe FlyActing FDA head vows to block political interference, Endpoint News says
20d ago
AZN
BMY
AstraZeneca’s ASCEND Obesity Trial Completion Puts New Weight Loss Combo in Focus
Premium
Company Announcements
AstraZeneca’s ASCEND Obesity Trial Completion Puts New Weight Loss Combo in Focus
21d ago
AZN
AstraZeneca: Late-Stage Pipeline Strength and Lung Cancer Upside Support Buy Rating and Unchanged 16,500 GBp Price Target
Premium
Ratings
AstraZeneca: Late-Stage Pipeline Strength and Lung Cancer Upside Support Buy Rating and Unchanged 16,500 GBp Price Target
21d ago
AZN
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
22d ago
AZN
BMY
AstraZeneca announces additional results from Phase III Serena-6 trial
PremiumThe Fly
AstraZeneca announces additional results from Phase III Serena-6 trial
22d ago
AZN
AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial
PremiumThe Fly
AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial
22d ago
AZN
AstraZeneca Adds Employee Scheme Shares to London Listing
PremiumCompany Announcements
AstraZeneca Adds Employee Scheme Shares to London Listing
23d ago
AZN
AstraZeneca Confirms Total Voting Rights at 1.55 Billion Shares
PremiumCompany AnnouncementsAstraZeneca Confirms Total Voting Rights at 1.55 Billion Shares
23d ago
AZN
AIM ImmunoTech enrolls final subject in pancreatic cancer development program
Premium
The Fly
AIM ImmunoTech enrolls final subject in pancreatic cancer development program
23d ago
AIM
AZN
AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi
Premium
The Fly
AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi
23d ago
AZN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >